Long_limb_DS: Duodenal Switch With a Standard Versus Long Alimentary Limb

Sponsor
Laval University (Other)
Overall Status
Completed
CT.gov ID
NCT03097926
Collaborator
(none)
20
2
58

Study Details

Study Description

Brief Summary

The aim of this study was to determine if Biliopancreatic Diversion with Duodenal Switch (BPD-DS) with a longer strict alimentary limb at the expense of a shorter biliopancreatic limb will offer significant weight lost, but with lesser gastrointestinal complaints, protein deficiency, vitamin and trace element deficit compared to standard BPD-DS.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Long alimentary limb BPD-DS
N/A

Detailed Description

This two-group, randomized, single-blind pilot study is conducted in a university-affiliated tertiary care center. The study protocol was approved by our ethic committee. Enrollment and randomization of the patients occurred between May 20163 and June 2015. Patients are undergoing follow-up evaluation. Patients were initially referred to our center for a bariatric surgery evaluation. Eligible patients were 18 years of age or older and met the criteria for a laparoscopic biliopancreatic diversion. Patients were excluded if they had a BMI ≥ 50 mg/m², a pacemaker, cirrhosis or if they were planing pregnancy in the next 2 years. Each patient was required to provide written informed consent. Patients were randomly assigned in a 1:1 ratio to undergo a standard biliopancreatic diversion (control group) or a modified biliopancreatic diversion with a longer strict alimentary limb (study group). A sealed envelope with the assignation was given to the surgeon in the operation room just before the procedure. Patients are followed every 6 months after surgery, up to 24-months for clinical evaluation, resolution of comorbidities, evaluation of side-effects, quality of life, bioimpedance testing and bloodwork.

Study Design

Study Type:
Interventional
Actual Enrollment :
20 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Care Provider)
Primary Purpose:
Treatment
Official Title:
Prospective Randomized Trial of Duodenal Switch With a Standard Versus Long Alimentary Limb.
Study Start Date :
May 1, 2013
Actual Primary Completion Date :
Mar 1, 2018
Actual Study Completion Date :
Mar 1, 2018

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Standard BPD-DS

Standard BPD-DS with a 250-cm alimentary limb and 100-cm common channel

Procedure: Long alimentary limb BPD-DS
BPD-DS with a long strict alimentary limb and a 100-cm common channel.

Experimental: Long alimentary limb BPD-DS

BPD-DS with a 100-cm common channel, a 100-cm biliary limb, the remaining bowel as the strict alimentary channel

Procedure: Long alimentary limb BPD-DS
BPD-DS with a long strict alimentary limb and a 100-cm common channel.

Outcome Measures

Primary Outcome Measures

  1. Total weight change [6, 12, 18, 24 months]

    Changes in total body weight, in kg, from baseline

Secondary Outcome Measures

  1. Changes in Gastro-intestinal side-effects scores [6,12,18,24 months]

    Gastro-intestinal symptoms assessed by measuring changes in GI Score

  2. Changes in Quality of life [6, 12, 18, 24 months]

    Measure of Quality of life using Short-Form 36

Other Outcome Measures

  1. Resolution of Type 2 Diabetes [6,12,18,24 months]

    Resolution rate of T2DM (based on normalized HbA1c without medication)

  2. Resolution of Hypertension [6,12,18,24 months]

    Resolution rate of hypertension, base on normalized blood pressure without medication

  3. Resolution of dyslipidemia [6,12,18,24 months]

    Percentage of patients with normalized cholesterol without medication

  4. Resolution of sleep apnea [6,12,18,24 months]

    Percentage of patients with normalized sleep apnea testing without airway support

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 60 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Candidates for a biliopancreatic diversion, BMI above 35 with comorbidities or above 40 without comorbidities
Exclusion Criteria:
  • BMI ≥ 50 mg/m², pacemaker, cirrhosis or planning pregnancy in the next 2 years, hypoalbuminemia, irritable bowel syndrome.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Laval University

Investigators

  • Principal Investigator: Laurent Biertho, MD, Quebec Heart and Lung Institute

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Laurent Biertho, Clinical Professor, Laval University
ClinicalTrials.gov Identifier:
NCT03097926
Other Study ID Numbers:
  • DS long Limb
First Posted:
Mar 31, 2017
Last Update Posted:
Mar 27, 2018
Last Verified:
Mar 1, 2018
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 27, 2018